QUOTE AND NEWS
Clusterstock  Apr 7  Comment 
With its beautiful weather and booming entertainment business, Southern California is one the most desirable places to live in the U.S. No surprise, then, that it's home to some of the wealthiest neighborhoods in the country, from Beverly Hills...
SeekingAlpha  Mar 25  Comment 
By Ross Klosterman: I had wanted to write this follow-up to my original article prior to La Jolla Pharmaceutical's (LJPC) Phase II data readout, but given I have been slugging through a particularly brutal "busy season" at work, this did not...
TheStreet.com  Mar 11  Comment 
NEW YORK (TheStreet) -- When speculative money is flowing into the stock market, as it is right now, I like to focus on biotech stocks. The biotech sector is on fire, so it's a great place for traders to find stocks ready to break out from...
TheStreet.com  Mar 11  Comment 
NEW YORK (TheStreet) -- La Jolla Pharmaceutical stock is seeing an astronomical rise on Tuesday on the news that the clinical trial for its galectin inhibitor -- used to treat chronic kidney disease -- was a success. CEO George Tidmarsh said,...
Benzinga  Mar 11  Comment 
Here's a look at the top tickers trending on StockTwits.com. La Jolla Pharmaceutical: Successful Phase 2 trial results Last night, La Jolla Pharmaceutical (NASDAQ: LJPC) reported that its Phase 2 trial of its GCS-100 chronic kidney disease...
StreetInsider.com  Mar 11  Comment 
Clean Diesel Technologies, Inc. (Nasdaq: CDTI) 116.3% HIGHER; announced that it has begun production of catalysts featuring CDTi's high-performance Mixed Phase Catalyst (MPC®) technology for Honda's 2015 Acura TLX model. Shipments are expected to...
Benzinga  Mar 11  Comment 
La Jolla Pharmaceutical Co (NASDAQ: LJPC) shares touched a new 52-week high of $18.86 on positive Phase 2 GCS-100 trial results in chronic kidney disease. FuelCell Energy (NASDAQ: FCEL) shares rose 16.54% to reach a new 52-week high of $4.58...
TheStreet.com  Mar 11  Comment 
SAN DIEGO (TheStreet) -- A few weeks ago, I called La Jolla Pharmaceuticals a "hedge fund roach motel" and expressed doubts about the company's galectin inhibitor GCS-100, in part because the dodgy history of the drug and the target.  Eh, I...
StreetInsider.com  Mar 11  Comment 
La Jolla Pharmaceutical Company. (NASDAQ: LJPC) 69% HIGHER; announced positive top-line results from its randomized, placebo-controlled Phase 2 trial of GCS-100 in chronic kidney disease (CKD). The trial met its primary efficacy endpoint of a...
StreetInsider.com  Mar 10  Comment 
La Jolla Pharmaceutical Company. (NASDAQ: LJPC) 24.2% HIGHER; announced positive top-line results from its randomized, placebo-controlled Phase 2 trial of GCS-100 in chronic kidney disease (CKD). The trial met its primary efficacy endpoint of a...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki